Johnson & Johnson $JNJ Stock Position Lessened by Flputnam Investment Management Co.

Key Points

• Flputnam Investment Management Co. reduced its shares in Johnson & Johnson by 14.8% in Q1, now holding 84,995 shares worth approximately $14.1 million.
• Analysts have given Johnson & Johnson an average rating of "Moderate Buy" with price targets ranging from $176 to $200.
• Johnson & Johnson is set to pay a quarterly dividend of $1.30, representing an annual yield of 2.9%, with a payout ratio of 55.61%.

Flputnam Investment Management Co. decreased its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 14.8% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 84,995 shares of the company's stock after selling 14,776 shares during the quarter. Flputnam Investment Management Co.'s holdings in Johnson & Johnson were worth $14,096,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of the stock. ICW Investment Advisors LLC grew its stake in Johnson & Johnson by 0.9% during the 1st quarter. ICW Investment Advisors LLC now owns 16,715 shares of the company's stock valued at $2,772,000 after acquiring an additional 147 shares in the last quarter. Graham Capital Management L.P. grew its stake in shares of Johnson & Johnson by 2.9% in the 1st quarter. Graham Capital Management L.P. now owns 114,555 shares of the company's stock valued at $18,998,000 after buying an additional 3,230 shares in the last quarter. Betterment LLC bought a new stake in shares of Johnson & Johnson in the 1st quarter valued at approximately $265,000. Retirement Planning Co of New England Inc. grew its stake in shares of Johnson & Johnson by 13.1% in the 1st quarter. Retirement Planning Co of New England Inc. now owns 5,945 shares of the company's stock valued at $986,000 after buying an additional 690 shares in the last quarter. Finally, Cura Wealth Advisors LLC grew its stake in shares of Johnson & Johnson by 11.9% in the 1st quarter. Cura Wealth Advisors LLC now owns 2,388 shares of the company's stock valued at $396,000 after buying an additional 253 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Analyst Ratings Changes

Several equities research analysts recently commented on JNJ shares. Morgan Stanley boosted their price target on Johnson & Johnson from $171.00 to $176.00 and gave the company an "equal weight" rating in a research note on Thursday, July 17th. Royal Bank Of Canada lifted their price objective on Johnson & Johnson from $181.00 to $185.00 and gave the company an "outperform" rating in a report on Thursday, July 17th. Erste Group Bank raised Johnson & Johnson from a "hold" rating to a "buy" rating in a report on Wednesday, July 23rd. Citigroup lifted their price objective on Johnson & Johnson from $185.00 to $200.00 and gave the company a "buy" rating in a report on Thursday, August 21st. Finally, Piper Sandler restated an "overweight" rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $176.29.

Johnson & Johnson Stock Performance

JNJ opened at $177.10 on Friday. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $181.16. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. The business's fifty day moving average is $165.99 and its 200-day moving average is $160.04. The firm has a market cap of $426.52 billion, a P/E ratio of 18.94, a price-to-earnings-growth ratio of 2.26 and a beta of 0.41.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The firm had revenue of $23.74 billion for the quarter, compared to analysts' expectations of $22.85 billion. During the same quarter in the previous year, the business posted $2.82 earnings per share. The business's revenue for the quarter was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Sell-side analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be given a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, August 26th. This represents a $5.20 annualized dividend and a yield of 2.9%. Johnson & Johnson's payout ratio is currently 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.